Clinical Trial Update: Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma [Phase 2]

View source ↗

Summary

This entry reports on a Phase 2 clinical trial evaluating upfront window therapy with irinotecan and carboplatin for newly diagnosed intermediate- or high-risk …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rhabdomyosarcoma

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Irinotecan (Irinotecan)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Sarcoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING